Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). 

Pharmaceutical

Karyopharm Therapeutics

Richard Paulson

Stephen Li

Amama Sadiq

Lisa DiPaolo

Mike Mano

Reshma Rangwala

Sohanya Cheng

James Accumanno

Michael Mason

Brian Austad

Leadership Team

Research and Development

Marketing and Communications

Clinical Operations

Finance and Accounting

Legal and Compliance

Teams at Karyopharm Therapeutics